OGT streamlines NGS library preparation. * September 28, 2026 OGT, a global provider of genomic research and diagnostic solutions has unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq NGS portfolio, compatible with the Hamilton NGS STAR Line. The latest advancement in OGT's ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets. Rising sample volumes are putting clinical research laboratories under pressure. Maintaining consistent throughput while managing labour-intensive library preparation is a growing bottleneck, one that OGT has addressed head-on. Developed in close collaboration with laboratory partners and workflow specialists, automation-enabled SureSeq workflows remove manual intervention at the most time-consuming stages of NGS library preparation, supporting high-throughput processing across multiple sample types. The result is a faster, more consistent process for NGS results without additional resource burden. "NGS automation is essential for high-volume laboratories to get the most out of their NGS analysis," said Adrian Smith, CEO of OGT. "By removing labour-intensive manual steps, laboratories can dramatically increase capacity, improve reproducibility and consistency allowing them to focus their teams where it matters most." Combined with OGT's wide range of haematological malignancy-focused SureSeq NGS panels, including the recently launched SureSeq Myeloid MRD Plus NGS Panel, SureSeq solutions give clinical research laboratories the throughput and confidence to extract clear, comprehensive genomics insights at scale.

OGT expands SureSeq(TM) Universal NGS Unique Dual Index (UDI) capabilities to support up to 384 samples per sequencing run. Helping high-throughput laboratories increase multiplexing capacity and maximise sequencing throughput without changing established workflows Oxford, UK, September 2026. OGT, a leading global provider of genomic research and diagnostic solutions, today announced the expansion of its SureSeq(TM) Universal NGS Unique Dual Index (UDI) range, enabling laboratories to multiplex up to 384 uniquely indexed samples in a single sequencing run. Compatible with existing SureSeq(TM) workflows and software, expanded UDI capabilities provide a straightforward path for laboratories looking to scale throughput while maintaining established processes and data quality. As sample volumes continue to increase, many high-throughput laboratories are looking for ways to maximise their NGS capacity without needing to modify existing workflows. The expanded SureSeq Universal NGS UDI offering addresses this challenge by increasing indexing capacity from 96 to 384 unique dual indexes. With this expansion, laboratories can process more samples and better utilise high-capacity Illumina sequencing systems, increasing operational efficiency and reducing per-sample run costs. Designed to integrate seamlessly with existing SureSeq workflows, the expanded UDI capability eliminates the need to modify workflow design. Laboratories can scale operations while continuing to work with the SureSeq solutions they already know and trust. "As sequencing demand continues to grow, laboratories need practical ways to increase throughput without adding complexity," said Gareth Thomson, Executive Vice President of Commercial Operations at OGT. "By expanding SureSeq Universal NGS indexing capacity to 384 samples per run, we're helping laboratories reduce batching constraints and costs per sample to maximise the value of their existing sequencing infrastructure. All the while, customers can still expect the same workflow consistency and performance they rely on from SureSeq." The expanded SureSeq Universal NGS UDI offering is designed to deliver performance equivalent to existing UDI 1-96 index sets while supporting confident, multiplexed sequencing through unique dual indexing. With the expanded offering of available UDIs, OGT continues its commitment to providing scalable genomic solutions created by scientists, for scientists. OGT's wide range of haematological malignancy-focused SureSeq NGS panels, including the recently launched SureSeq Myeloid MRD Plus NGS Panel, give clinical research labs the throughput and confidence to extract clear, comprehensive genomics insights at scale. OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell(R), CytoSure(R) and SureSeq(TM) ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 30 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership - together - we'll achieve more. CytoSure(R), SureSeq(TM) and myProbes(R): For Research Use Only, not for use in diagnostic procedures. CytoCell(R): Some products may not be available in your region. About Sysmex Corporation Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit www.sysmex.co.jp/en/. * "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan. Media Contact Information: